Which prostate cancer drug is safer for the heart? new study aims to find out
NCT ID NCT06330805
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 34 times
Summary
This study compares two hormone therapies—relugolix and leuprolide—given alongside radiation for prostate cancer. Researchers want to see which drug has less impact on heart function. About 70 men with intermediate-risk prostate cancer will take one of the two drugs for 6 months and undergo heart tests, exercise tests, and blood draws. The goal is to find out if relugolix is safer for the heart than the more commonly used leuprolide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.